Biotech to Fast Track Phase 3 Depression Trial
Source: Dr. Myles Minter  (10/30/25)
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report. More >

2 Key Catalysts Ahead for Developer of Psych Drugs
Source: Patrick Trucchio  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report. More >

Co. Speeds Up Development of New Drug for Depression
Source: Andrew Tsai  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report. More >

Price Target on Psychiatric Drug Biotech Boosted 200%
Source: Dr. Laura Chico  (10/27/25)
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report. More >

US Biopharma In-Licenses 3 New Assets
Source: Dr. Martin Fan  (10/24/25)
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report. More >

Chen's High-Grade Gold, Silver Plays for Q4
Source: Streetwise Reports  (10/23/25)
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside? More >

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Source: Streetwise Reports  (10/20/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases. More >

Biopharma's New MASH Drug Has Two MOAs
Source: Patrick Trucchio  (10/15/25)
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report. More >

Life Sciences Co. Reports Strong Survival Data
Source: Jason Kolbert  (10/13/25)
OS Therapies Inc.'s (OSTX:NYSEAMERICAN) trial results are for its new immunotherapy in fully resected pulmonary metastatic osteosarcoma, noted a D. Boral Capital report. More >

Pharma Announces Faster Approval Pathway for Neurodegenerative Disease
Source: Dr. Leland Gershell and Rohan Mathur  (10/9/25)
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases. More >

Therapeutics Company Advances Gene Therapy Breakthrough
Source: Mitchell Kapoor and Dr. Raghuram Selvaraju  (10/9/25)
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval. More >

New Drug for Duchenne Muscular Dystrophy Nears Potential Approval
Source: James Molloy  (10/6/25)
Capricor Therapeutics Inc. (CAPR:NASDAQ) could receive a PDUFA date for its cell therapy as early as spring 2026 if it follows the FDA-outlined path forward, noted an Alliance Global Partners report. More >

Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy
Source: Streetwise Reports  (10/1/25)
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space. More >

Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Source: Brian Abrahams  (9/29/25)
Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development. More >

Biotech Discovers Breakthrough DMD Therapy Opportunity
Source: Dr. Leland Gershell  (9/26/25)
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc. More >

Healthcare Firm Targets Alzheimer's With Technology Breakthrough
Source: Streetwise Reports  (9/5/25)
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need. More >

Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Source: Dr. Douglas Loe  (9/5/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report. More >

New Remission Data on MG Patients Compelling
Source: Mitchell Kapoor  (9/5/25)
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. More >

Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada
Source: Streetwise Reports  (9/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology. More >

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial
Source: Streetwise Reports  (9/3/25)
Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart. More >

Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada
Source: Jason Wittes  (8/11/25)
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note. More >

Biotech Announces Topline Results From Cardiovascular Drug Trial
Source: Brandon Folkes  (8/11/25)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis. More >

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment
Source: Streetwise Reports  (8/11/25)
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock. More >

Canadian Pharma Finds Promising Cardiovascular Breakthrough
Source: Douglas Loe  (8/8/25)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock. More >

Clean Tech Firm Making Important PFAS Breakthrough
Source: Streetwise Reports  (7/29/25)
Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders. More >